Lu sur https://www.ncbi.nlm.nih.gov/pubmed/28520084 cette brève intitulée
"Effets secondaires rénaux et hématologiques de la thérapie IVIg à long terme chez les patients atteints de troubles neurologiques."
Pour mémoire les IVIg (Intravenous Immunoglobulin) sont les cures d'immunoglobulines par intraveineuse
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
Renal and Hematologic Side Effects of Long term IVIG Therapy in Patients With Neurologic Disorders.
Levine AA1, Levine TD1, Clarke K1, Saperstein D1.
Muscle Nerve. 2017 May 18. doi: 10.1002/mus.25693.
PMID: 28520084 DOI: 10.1002/mus.25693
For patients receiving intravenous immunoglobulin (IVIg), renal and hemolytic side effects are well recognized. However, there is very little data on the effects of chronic IVIg therapy.
We retrospectively analyzed laboratory data on 166 patients who received IVIgfor 12 months with dosing from 0.441 gm/kg/month to 2.58 gm/kg/month, measuring changes in hematocrit and glomerular filtration rates (GFR) at 6 and 12 months.
Of the 2,232 infusions, there were no incidents of clinical hemolysis. However, after 12 months of treatment, 21% of patients had a 3 g/dl or greater decline in their hematocrit and 10% experienced a 20% or greater decline in GFR
No clinically significant hemolysis was observed in patients receiving chronic IVIg therapy. However, a significant number of patients experienced a decline in hematocrit and/or GFR while on therapy. This emphasizes the need for observation of hematologic and renal function in patients treated with chronic IVIg.